Side Effects of Imatinib Mesylate

Imatinib Mesylate is a targeted therapy widely used in the treatment of certain cancers such as Chronic Myeloid Leukemia and gastrointestinal stromal tumors. While it has significantly improved patient outcomes, it is associated with a range of side effects that vary in severity.

Common and Serious Side Effects

Costly: The drug therapy is very expensive which is not affordable to people.

1. The serious side effect of Imatinib Mesylate is Liver Toxicity.
2. The severe side effects may include fluid retention, gastrointestinal bleeding, bone marrow suppression, liver problems, and heart failure.
3. The use of the drug during pregnancy may result in harm to the baby.
4. Fertility, meaning your ability to conceive or father a child, may be affected by Imatinib Mesylate.
5. Low blood counts: The white blood cells, red blood cells, and platelets may temporarily decrease. This results in increased risk for infection, anemia and/or bleeding.
6. Imatinib Mesylate is less effective in patients with the D816V mutation in c-KIT systemic mastocytosis as this is not able to inhibit the kinase activity of the D816V mutant of c-KIT.
7. Due to this drug therapy, the victim suffers from Headache, Fatigue, Joint pain, Indigestion (heartburn), Abdominal pain, Cough, Shortness of breath, Poor appetite, Constipation, and Night sweats (skin reactions).
8. The several other side-effects include Nose bleeds (bleeding problems), Weakness, Diarrhea, Fever, Hemorrhage, and Edema (swelling of the face, feet, hands).
9. Nausea and vomiting.

Read Also: Drug Therapy for Cancer Treatment Overview

Market Insights

Growing Demand and Market Drivers

The global market for Imatinib and similar targeted therapies continues to expand, driven by increasing cancer prevalence and advancements in precision medicine. The success of Imatinib as one of the first targeted cancer therapies has paved the way for the development of newer tyrosine kinase inhibitors.

Cost and Accessibility Challenges

Despite its clinical benefits, cost remains a significant barrier in many regions. Although generic versions have improved affordability, access is still limited in low- and middle-income countries. Pricing pressures and healthcare policy reforms are shaping market dynamics.

Competitive Landscape

The market has become increasingly competitive with the introduction of second- and third-generation tyrosine kinase inhibitors, which offer improved efficacy in resistant cases. Pharmaceutical companies are focusing on innovation, lifecycle management, and combination therapies to maintain market share.

About Effectual Services

Effectual Services is an award-winning Intellectual Property (IP) management advisory & consulting firm offering IP intelligence to Fortune 500 companies, law firms, research institutes and universities, and venture capital firms/PE firms, globally. Through research & intelligence we help our clients in taking critical business decisions backed with credible data sources, which in turn helps them achieve their organisational goals, foster innovation and achieve milestones within timelines while optimising costs.

We are one of the largest IP & business intelligence providers, globally serving clients for over a decade now. Our multidisciplinary teams of subject matter experts have deep knowledge of best practices across industries, are adept with benchmarking quality standards and use a combination of human and machine intellect to deliver quality projects. Having a global footprint in over 5 countries helps us to bridge boundaries and work seamlessly across multiple time zones, thus living to the core of our philosophy - Innovation is global, so are we !!!

Follow Us: LinkedIn, Twitter